Immunological Data Discovery Index
Immunological Data Discovery Index
| identifier: | SDY1108 |
| description: |
A systems approach reveals that engagement of systemic immunity is critical to the process of tumor rejection following immunotherapy. Using a spontaneous model of triple-negative breast cancer, we assessed immune cell dynamics across the organism during tumor rejection
|
| aggregation: |
instance of dataset
|
| refinement: |
2 - Complete set of descriptive data and results, as ascertained by ImmPort.
|
| availability: |
available with registration
|
| primaryPublications: |
28111070 |
| isAbout: |
By using mass CyTOF to systematically characterizing diverse cell subsets and their activation states simultaneously under different treatment conitions in a spontaneous mouse model of triple-negative breast cancer. To assess immune cell dynamics across the organism during tumor rejection, the lab developed intuitive models for visualizing single-cell data with statistical inference. To conduct validations on the hypothesis generated from the global analysis results.
|
| clinical trial: | |
| study category: | Oncology |
| study type: | Interventional |
| subject species: | Mus musculus |
| biosample type: |
Bone Marrow Lymph node Other Spleen Whole blood |
| subject gender: | Both |
| assay type: | CyTOF |
| name: |
cancer immunotherapy
|
| fullName: |
Matthew Spitzer
Garry Nolan
Edgar Engleman
|
| affiliations: |
UCSF+Stanford University
Stanford University
|
| roles: |
principal investigator
|
| name: |
Systemic Immunity for Cancer Immunotherapy
|
| size: |
13
|
| output: |
Mass CyTOF, Scaffold maps, Cell population profiles in MMTV models, BP melanoma models, and metastatic melanoma patients on clinical trial, Adoptive T Cell Transfer study, and Statistical Scaffold in R. The highlighted results: System-wide models reveal coordinated anti-tumor immunity across the organism, Tumor eradication requires immune activation in the periphery, Network analysis identifies CD4 T cells sufficient to initiate immune responses, PD-L1 upregulation early post-therapy protects distal tumors from systemic immunity
|
| studyGroups: |
MMTV_UnTreated_Day3: no treatment to MMTV mice,a spontaneous model of triple-negative breast cancer, sample collected at day3
MMTV_UnTreated_Day8: no treatment to MMTV mice, sample collected at day8 (matched to treatment group)
MMTV_B6Antibodies_Day3: effective tumor-binding antibody therapy, B6-alloIgG + anti-CD40 + IFNg, priming phase
MMTV_B6Antibodies_Day8: effective tumor-binding antibody therapy, B6-alloIgG + anti-CD40 + IFNg, rejection phase
MMTV_CD1Antibodies_Day3: effective tumor-binding antibody therapy, CD-1-alloIgG + anti-CD40 + IFNg, priming phase
MMTV_CD1Antibodies_Day8: effective tumor-binding antibody therapy, CD-1-alloIgG + anti-CD40 + IFNg, rejection phase
MMTV_antiPD1_Day3: ineffective therapy, anti-PD-1, priming phase
MMTV_antiPD1_Day8: ineffective therapy, anti-PD-1, rejection phase
MMTV_CD4_Tcell_transfer: therapy of effective CD4 T cells transfer to naive MMTV mice, time series assay
BP_ineffective: ineffctive therapy in the inducible mouse model of melanoma driven by Braf^V600E and loss of Pten
BP_effective: effective therapy in the inducible mouse model of melanoma driven by Braf^V600E and loss of Pten
MMTV_vehicle: vehicle control to MMTV mice with multi-focal disease after tumor-binding antibody therapy
MMTV_antiPD-L1: antiPD-L1 therapy combined with tumor-binding antibody therapy to MMTV mice with multi-focal disease
hum_responder: metastatic melanoma patients responded to the therapy of anti-CTLA-4 antibodies (Ipilimumab) in combination with GM-CSF
hum_non-responders: metastatic melanoma patients patients did not respond to the therapy of anti-CTLA-4 antibodies (Ipilimumab) in combination with GM-CSF
|
| description: |
A systems approach reveals that engagement of systemic immunity is critical to the process of tumor rejection following immunotherapy. Using a spontaneous model of triple-negative breast cancer, we assessed immune cell dynamics across the organism during tumor rejection
|
| identifier: |
10.21430/M3L410EFMQ
|
| startDate: |
2015-01-01
|
| name: |
ImmPort
|
| identifier: |
SCR:012804
|
| homePage: |
http://www.immport.org |
